Affinity DataIC50: 0.180nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 0.410nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 0.420nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1/2(Homo sapiens (Human))
University of Auckland
Curated by ChEMBL
University of Auckland
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of MEK assessed as inhibition of ERK phosphorylation by Raf-MEK-ERK cascade assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4A/4B/4C/4D(Homo sapiens (Human))
Pfizer
Curated by ChEMBL
Pfizer
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of PDE4 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetDNA-dependent protein kinase catalytic subunit(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetDNA-dependent protein kinase catalytic subunit(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetDNA-dependent protein kinase catalytic subunit(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1/2(Homo sapiens (Human))
University of Auckland
Curated by ChEMBL
University of Auckland
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of MEK in mouse colon 26 carcinoma cells assessed as inhibition of ERK phosphorylation by ELISAMore data for this Ligand-Target Pair
TargetDNA-dependent protein kinase catalytic subunit(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetDNA-dependent protein kinase catalytic subunit(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetDNA-dependent protein kinase catalytic subunit(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: <2nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
Affinity DataIC50: 2.20nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 2.5nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 2.5nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 2.5nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 2.60nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 2.80nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 3.30nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 3.40nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 3.80nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1/2(Homo sapiens (Human))
University of Auckland
Curated by ChEMBL
University of Auckland
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of MEK in mouse colon 26 carcinoma cells assessed as inhibition of ERK phosphorylation by ELISAMore data for this Ligand-Target Pair
Affinity DataIC50: 4.5nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 4.70nMAssay Description:Inhibition of PDE2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 4.90nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1/2(Homo sapiens (Human))
University of Auckland
Curated by ChEMBL
University of Auckland
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of MEK in mouse colon 26 carcinoma cells assessed as inhibition of ERK phosphorylation by ELISAMore data for this Ligand-Target Pair
Affinity DataIC50: 6nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 6.30nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 6.30nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 6.80nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 7.70nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 9.30nMAssay Description:Inhibition of PDE2 catalytic domain (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 9.90nMpH: 7.5Assay Description:Recombinant human NQO1 was obtained from Sigma and diluted in 50 mM phosphate buffer to give an absorbance of 0.1 at 550 nm; 5 uL of this solution wa...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetDNA-dependent protein kinase catalytic subunit(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: 11nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair
TargetDNA-dependent protein kinase catalytic subunit(Homo sapiens (Human))
Mekanistic Therapeutics
US Patent
Mekanistic Therapeutics
US Patent
Affinity DataIC50: 11nMAssay Description:Z′-LYTEŽ Assay Conditions: Test Compounds: The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold seri...More data for this Ligand-Target Pair